INDINIVIR SULFATE

Indinivir Sulfate Adverse Events Reported to the FDA Over Time

How are Indinivir Sulfate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Indinivir Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Indinivir Sulfate is flagged as the suspect drug causing the adverse event.

Most Common Indinivir Sulfate Adverse Events Reported to the FDA

What are the most common Indinivir Sulfate adverse events reported to the FDA?

Lipodystrophy Acquired	35 (4.05%)
Portal Hypertension	23 (2.66%)
Eyelid Ptosis	19 (2.2%)
Abdominal Distension	14 (1.62%)
Diplopia	14 (1.62%)
Immune Reconstitution Syndrome	14 (1.62%)
Mitochondrial Toxicity	14 (1.62%)
Progressive External Ophthalmoplegi...	14 (1.62%)
Portal Vein Thrombosis	13 (1.5%)
Hepatic Failure	11 (1.27%)
Blood Lactic Acid Increased	10 (1.16%)
	Show More
Lactic Acidosis	10 (1.16%)
Portal Hypertensive Gastropathy	10 (1.16%)
Sepsis	10 (1.16%)
Abdominal Pain	9 (1.04%)
Constipation	9 (1.04%)
Mitochondrial Cytopathy	9 (1.04%)
Candidiasis	8 (.93%)
Drug Resistance	8 (.93%)
Malignant Melanoma	8 (.93%)
Pulmonary Hypertension	8 (.93%)
Varices Oesophageal	8 (.93%)
Blood Creatine Phosphokinase Increa...	7 (.81%)
Drug Exposure During Pregnancy	7 (.81%)
Escherichia Infection	7 (.81%)
Hypoventilation	7 (.81%)
Metastases To Lymph Nodes	7 (.81%)
Nodular Regenerative Hyperplasia	7 (.81%)
Pyrexia	7 (.81%)
Abdominal Hernia	6 (.69%)
Cardiac Murmur	6 (.69%)
Cryptorchism	6 (.69%)
Metastases To Skin	6 (.69%)
Virologic Failure	6 (.69%)
Anaemia	5 (.58%)
Aspartate Aminotransferase Increase...	5 (.58%)
Blood Creatinine Increased	5 (.58%)
Congenital Anomaly	5 (.58%)
Diarrhoea	5 (.58%)
Nephrolithiasis	5 (.58%)
Neuropathy Peripheral	5 (.58%)
Oesophageal Varices Haemorrhage	5 (.58%)
Ophthalmoplegia	5 (.58%)
Pneumocystis Jiroveci Pneumonia	5 (.58%)
Pneumonia	5 (.58%)
Progressive Multifocal Leukoencepha...	5 (.58%)
Rash	5 (.58%)
Splenomegaly	5 (.58%)
Ascites	4 (.46%)
Blood Hiv Rna Increased	4 (.46%)
Blood Ph Abnormal	4 (.46%)
Bundle Branch Block Left	4 (.46%)
Cd4 Lymphocytes Decreased	4 (.46%)
Drug Toxicity	4 (.46%)
Fatigue	4 (.46%)
Hyperlipidaemia	4 (.46%)
Lipoatrophy	4 (.46%)
Myalgia	4 (.46%)
Neoplasm Malignant	4 (.46%)
Oesophageal Candidiasis	4 (.46%)
Osteonecrosis	4 (.46%)
Renal Failure	4 (.46%)
Supraventricular Tachycardia	4 (.46%)
Viral Mutation Identified	4 (.46%)
Acute Chest Syndrome	3 (.35%)
Acute Respiratory Distress Syndrome	3 (.35%)
Asthenia	3 (.35%)
Blood Ph Decreased	3 (.35%)
Cachexia	3 (.35%)
Confusional State	3 (.35%)
Depression	3 (.35%)
Drug Ineffective	3 (.35%)
Drug Interaction	3 (.35%)
General Physical Health Deteriorati...	3 (.35%)
Hepatobiliary Disease	3 (.35%)
Hepatotoxicity	3 (.35%)
Lethargy	3 (.35%)
Liver Disorder	3 (.35%)
Metastasis	3 (.35%)
Oral Candidiasis	3 (.35%)
Pancreatitis	3 (.35%)
Pancreatitis Chronic	3 (.35%)
Pyonephrosis	3 (.35%)
Renal Colic	3 (.35%)
Renal Tubular Disorder	3 (.35%)
Respiratory Distress	3 (.35%)
Respiratory Failure	3 (.35%)
Therapeutic Response Decreased	3 (.35%)
Tongue Disorder	3 (.35%)
Tuberculosis	3 (.35%)
Vomiting	3 (.35%)
Adverse Drug Reaction	2 (.23%)
Alanine Aminotransferase Increased	2 (.23%)
Bacterial Sepsis	2 (.23%)
Bleeding Varicose Vein	2 (.23%)
Blood Alkaline Phosphatase Increase...	2 (.23%)
Blood Bilirubin Increased	2 (.23%)
Blood Triglycerides Increased	2 (.23%)
Candida Serology Positive	2 (.23%)
Cardiac Arrest	2 (.23%)
Cd4 Lymphocytes Increased	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Indinivir Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Indinivir Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Indinivir Sulfate

What are the most common Indinivir Sulfate adverse events reported to the FDA?

Hepatic And Hepatobiliary	75 (8.68%)
Skin And Subcutaneous Tissue	39 (4.51%)
Infections - Pathogen Unspecified	38 (4.4%)
Gastrointestinal Signs	30 (3.47%)
Therapeutic And Nontherapeutic Effe...	30 (3.47%)
Ocular Neuromuscular	25 (2.89%)
Fungal Infectious	24 (2.78%)
Metabolism	23 (2.66%)
Respiratory	21 (2.43%)
Metabolic, Nutritional And Blood Ga...	18 (2.08%)
Viral Infectious	17 (1.97%)
	Show More
Gastrointestinal Hemorrhages	16 (1.85%)
Immunodeficiency Syndromes	16 (1.85%)
Metastases	16 (1.85%)
Cardiac Arrhythmias	15 (1.74%)
Cytoplasmic Disorders Congenital	15 (1.74%)
Gastrointestinal Motility And Defec...	14 (1.62%)
Vision	14 (1.62%)
Chemical Injury And Poisoning	13 (1.5%)
Hematology Investigations	13 (1.5%)
Microbiology And Serology	13 (1.5%)
Acid-base	12 (1.39%)
Hepatobiliary	12 (1.39%)
Bacterial Infectious	11 (1.27%)
Neurological	11 (1.27%)
Enzyme	10 (1.16%)
Gastrointestinal Vascular Condition...	10 (1.16%)
Renal And Urinary Tract Investigati...	9 (1.04%)
Spleen, Lymphatic And Reticulendoth...	9 (1.04%)
Pulmonary Vascular	8 (.93%)
Reproductive Tract And Breast Disor...	8 (.93%)
Skin Neoplasms Malignant And Unspec...	8 (.93%)
Urinary Tract Signs	8 (.93%)
Abdominal Hernias And Other Abdomin...	7 (.81%)
Body Temperature Conditions	7 (.81%)
Cardiac And Vascular Investigations	7 (.81%)
Epidermal And Dermal Conditions	7 (.81%)
Muscle	7 (.81%)
Renal Disorders	7 (.81%)
Anemias Nonhemolytic And Marrow Dep...	6 (.69%)
Exocrine Pancreas Conditions	6 (.69%)
Lipid Metabolism	6 (.69%)
Miscellaneous And Site Unspecified ...	6 (.69%)
Ocular Infections, Irritations And ...	6 (.69%)
Oral Soft Tissue Conditions	6 (.69%)
Peripheral Neuropathies	6 (.69%)
Urolithiases	6 (.69%)
Congenital And Hereditary	5 (.58%)
Depressed Mood Disorders	5 (.58%)
Movement Disorders	5 (.58%)
Mycobacterial Infectious	5 (.58%)
White Blood Cell	5 (.58%)
Appetite And General Nutritional	4 (.46%)
Bone Disorders	4 (.46%)
Lower Respiratory Tract Disorders	4 (.46%)
Nephropathies	4 (.46%)
Ocular Structural Change, Deposit A...	4 (.46%)
Peritoneal And Retroperitoneal Cond...	4 (.46%)
Coronary Artery	3 (.35%)
Deliria	3 (.35%)
Embolism And Thrombosis	3 (.35%)
Gastrointestinal Conditions	3 (.35%)
Headaches	3 (.35%)
Hemoglobinopathies	3 (.35%)
Lipid Analyses	3 (.35%)
Medication Errors	3 (.35%)
Physical Examination Topics	3 (.35%)
Tongue Conditions	3 (.35%)
Vascular Hypertensive	3 (.35%)
Blood And Lymphatic System Disorder...	2 (.23%)
Central Nervous System Vascular	2 (.23%)
Cornification And Dystrophic Skin	2 (.23%)
Cranial Nerve Disorders	2 (.23%)
Encephalopathies	2 (.23%)
Gastrointestinal Tract Disorders Co...	2 (.23%)
Glucose Metabolism Disorders	2 (.23%)
Injuries	2 (.23%)
Lifestyle Issues	2 (.23%)
Maternal Complications Of Pregnancy	2 (.23%)
Myocardial	2 (.23%)
Platelet	2 (.23%)
Psychiatric And Behavioural Symptom...	2 (.23%)
Respiratory And Pulmonary Investiga...	2 (.23%)
Seizures	2 (.23%)
Tissue	2 (.23%)
Upper Respiratory Tract Disorders	2 (.23%)
Venous Varices	2 (.23%)
Abortions And Stillbirth	1 (.12%)
Allergic Conditions	1 (.12%)
Anxiety Disorders	1 (.12%)
Bone And Joint Therapeutic Procedur...	1 (.12%)
Bone, Calcium, Magnesium And Phosph...	1 (.12%)
Coagulopathies And Bleeding Diathes...	1 (.12%)
Electrolyte And Fluid Balance Condi...	1 (.12%)
Food Intolerance Syndromes	1 (.12%)
Gallbladder	1 (.12%)
Hematological	1 (.12%)
Hepatobiliary Therapeutic Procedure...	1 (.12%)
Increased Intracranial Pressure And...	1 (.12%)
Investigations, Imaging And Histopa...	1 (.12%)
Joint	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Indinivir Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Indinivir Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.